The DOI matches its Crossref record; 66 of the 66 references it cites were found in a registry or an index.
Systemic lupus erythematosus in three ethnic groups: XVI. Association of hydroxychloroquine use with reduced risk of damage accrual
Abstract
Objective: To examine whether hydroxychloroquine (HCQ) usage is associated with a reduced risk of damage accrual in patients with systemic lupus erythematosus (SLE). Methods: Patients (n = 518) meeting the American College of Rheumatology criteria for diagnosis of SLE and with ≤5 years disease duration at study entry were followed up annually. Socioeconomic, demographic, clinical, and serologic manifestations as well as disease activity (by the Systemic Lupus Activity Measure [SLAM]) and damage (by the Systemic Lupus International Collaborating Clinics damage index [SDI]) were measured. Propensity scores were calculated to adjust for confounding factors affecting treatment assignment. A Cox proportional hazards model was used to compare the risk of developing new damage according to HCQ use at enrollment into the study. Results: Fifty‐six percent of the patients were treated with HCQ at the time of study enrollment. Patients who were not treated with HCQ on enrollment had higher SLAM and SDI scores than patients who were treated. Untreated patients were significantly more likely to have major organ involvement such as renal disease (P < 0.0001) or central nervous system disease (P < 0.0025). Results of unadjusted analysis suggested that treated patients were less likely to accrue damage (hazard ratio [HR] 0.68). With adjustment for differences in treatment assignment, HCQ usage was still associated with a reduced risk of developing new damage, with an HR of 0.68 (95% confidence interval [95% CI] 0.53–0.93) (P = 0.014). With adjustment for differences in treatment assignment, HCQ usage was still associated with a reduced risk of developing new damage (HR 0.73 [95% CI 0.52–1.00]) (P = 0.05). However, patients receiving HCQ who had no damage at study entry had a statistically significant decrease in the risk of damage accrual (HR 0.55 [95% CI 0.34–0.87]) (P = 0.0111), whereas those receiving HCQ who had damage at study entry did not (HR 1.106 [95% CI 0.70–1.74]) (P = 0.6630). Conclusion: These findings indicate that, after adjustment for propensity to receive HCQ, HCQ usage is independently associated with a reduced risk of damage accrual in SLE patients who had not yet accrued damage at the time of treatment initiation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The 1982 revised criteria for the classification of systemic lupus erythematosus
Tan, E. M., Cohen, A. S., Fries, J. F., Masi, A. T., Mcshane, D. J., Rothfield, N. F., Schaller, J. G., Talal, N., & Winchester, R. J. (1982) · Arthritis & Rheumatism · doi:10.1002/art.1780251101 · Cited by 14,519
Estimating Causal Effects from Large Data Sets Using Propensity Scores
Rubin, D. B. (1997) · Annals of Internal Medicine · doi:10.7326/0003-4819-127-8_part_2-199710151-00064 · Cited by 2,877
Gladman, D., Ginzler, E., Goldsmith, C., Fortin, P., Liang, M., Sanchez‐Guerrero, J., Urowitz, M., Bacon, P., Bombardieri, S., Hanly, J., et al. (1996) · Arthritis & Rheumatism · doi:10.1002/art.1780390303 · Cited by 2,582
Cervera, R., Khamashta, M. A., Font, J., Sebastiani, G. D., Gil, A., Lavilla, P., Mejía, J. C., Aydintug, A. O., Chwalinska-Sadowska, H., de Ramón, E., et al. (2003) · Medicine · doi:10.1097/01.md.0000091181.93122.55 · Cited by 1,377
Liang, M. H., Socher, S. A., Larson, M. G., & Schur, P. H. (1989) · Arthritis & Rheumatism · doi:10.1002/anr.1780320909 · Cited by 789
Gladman, D. D., Urowitz, M. B., Goldsmith, C. H., Fortin, P., Ginzler, E., Gordon, C., Hanly, J. G., Isenberg, D. A., Kalunian, K., Nived, O., et al. (1997) · Arthritis & Rheumatism · doi:10.1002/art.1780400506 · Cited by 759
(1991) · New England Journal of Medicine · doi:10.1056/nejm199101173240303 · Cited by 677
Damage in systemic lupus erythematosus and its association with corticosteroids
Zonana-Nacach, A., Barr, S. G., Magder, L. S., & Petri, M. (2000) · Arthritis & Rheumatism · doi:10.1002/1529-0131(200008)43:8<1801::aid-anr16>3.0.co;2-o · Cited by 495
Mechanism of action of hydroxychloroquine as an antirheumatic drug
Fox, R. I. (1993) · Seminars in Arthritis and Rheumatism · doi:10.1016/s0049-0172(10)80012-5 · Cited by 430
Cervera, R., Khamashta, M. A., Font, J., Sebastiani, G. D., Gil, A., Lavilla, P., Aydintug, A. O., Jedryka-Góral, A., Ramón, E. D., Fernández-Nebro, A., et al. (1999) · Medicine · doi:10.1097/00005792-199905000-00003 · Cited by 430
Lupus erythematosus in the 1980s: A survey of 570 patients
Pistiner, M., Wallace, D. J., Nessim, S., Metzger, A. L., & Klinenberg, J. R. (1991) · Seminars in Arthritis and Rheumatism · doi:10.1016/0049-0172(91)90057-7 · Cited by 403
Erkan, D. (2002) · Rheumatology · doi:10.1093/rheumatology/41.8.924 · Cited by 330
Illei, G. G., Takada, K., Parkin, D., Austin, H. A., Crane, M., Yarboro, C. H., Vaughan, E. M., Kuroiwa, T., Danning, C. L., Pando, J., et al. (2002) · Arthritis & Rheumatism · doi:10.1002/art.10142 · Cited by 329
Alarc�n, G. S., McGwin, Jr., Bastian, H. M., Roseman, J., Lisse, J., Fessler, B. J., Friedman, A. W., Reveille, J. D., & LUMINA Study Group (2001) · Arthritis & Rheumatism · doi:10.1002/1529-0131(200104)45:2<191::aid-anr173>3.0.co;2-2 · Cited by 325
Self-citationPetri, M., Lakatta, C., Magder, L., & Goldman, D. (1994) · The American Journal of Medicine · doi:10.1016/0002-9343(94)90151-1 · Cited by 323
Alarcón, G. S., Friedman, A. W., Straaton, K. V., Moulds, J. M., Lisse, J., Bastian, H. M., McGwin, G., Bartolucci, A. A., Roseman, J. M., & Reveille, J. D. (1999) · Lupus · doi:10.1191/096120399678847704 · Cited by 309
Self-citationBoumpas, D. T., Austin, H. A., Fessler, B. J., Balow, J. E., Klippel, J. H., & Lockshin, M. D. (1995) · Annals of Internal Medicine · doi:10.7326/0003-4819-122-12-199506150-00009 · Cited by 303
Self-citationA Long-Term Study of Hydroxychloroquine Withdrawal on Exacerbations in Systemic Lupus Erythematosus
The Canadian Hydroxychloroquine Study Group, Tsakonas, E., Joseph, L., Esdaile, J. M., Choquette, D., Senécal, J.-L., Cividino, A., Danoff, D., Osterland, C. K., Yeadon, C., et al. (1998) · Lupus · doi:10.1191/096120398678919778 · Cited by 293
Rahman, P., Gladman, D. D., Urowitz, M. B., Hallett, D., & Tam, L. S. (2001) · Lupus · doi:10.1191/096120301670679959 · Cited by 288
Vascular Stiffness in Women With Systemic Lupus Erythematosus
Selzer, F., Sutton-Tyrrell, K., Fitzgerald, S., Tracy, R., Kuller, L., & Manzi, S. (2001) · Hypertension · doi:10.1161/01.hyp.37.4.1075 · Cited by 287
van den Borne, B. E. E. M., Dijkmans, B. A. C., de ROOY, H. H., le Cessie, S., & Verweij, C. (1997) · PubMed · Cited by 281
Hydroxychloroquine use in the Baltimore Lupus Cohort: effects on lipids, glucose and thrombosis
Petri, M. (1996) · Lupus · doi:10.1177/0961203396005001051 · Cited by 260
Reveille, J. D., Moulds, J. M., Ahn, C. W., Friedman, A., Baethge, B. A., Roseman, J. M., Straaton, K. V., Alarc�n, G. S., & the Lumina Study Group (1998) · Arthritis & Rheumatism · Cited by 244
Self-citationHydroxychloroquine Reverses Platelet Activation Induced by Human IgG Antiphospholipid Antibodies
Espinola, R., Ghara, A., Harris, E., & Pierangeli, S. (2002) · Thrombosis and Haemostasis · doi:10.1055/s-0037-1613033 · Cited by 240
Wallace, D. J., Metzger, A. L., Stecher, V. J., Turnbull, B. A., & Kern, P. A. (1990) · The American Journal of Medicine · doi:10.1016/0002-9343(90)90345-e · Cited by 230
Karlson, E. W., Daltroy, L. H., Lew, R. A., Wright, E. A., Partridge, A. J., Fossel, A. H., Roberts, W. N., Stern, S. H., Straaton, K. V., Wacholtz, M. C., et al. (1997) · Arthritis & Rheumatism · doi:10.1002/art.1780400108 · Cited by 223
Alarc�n, G. S., Roseman, J. M., Bartolucci, A. A., Friedman, A., Moulds, J. M., Goel, N., Straaton, K. V., Reveille, J. D., & the Lumina Study Group (1998) · Arthritis & Rheumatism · Cited by 206
Self-citationRahman, P., Gladman, D. D., Urowitz, M. B., Yuen, K., Hallett, D. C., & Bruce, I. N. (1999) · PubMed · Cited by 199
Goldman, F. D., Gilman, A. L., Hollenback, C., Kato, R. M., Premack, B. A., & Rawlings, D. J. (2000) · Blood · doi:10.1182/blood.v95.11.3460 · Cited by 178
Thrombosis and Systemic Lupus Erythematosus: The Hopkins Lupus Cohort Perspective
Petri, M. (1996) · Scandinavian Journal of Rheumatology · doi:10.3109/03009749609069986 · Cited by 176
Gerstein, H. C., Thorpe, K. E., Wayne Taylor, D., & Brian Haynes, R. (2002) · Diabetes Research and Clinical Practice · doi:10.1016/s0168-8227(01)00325-4 · Cited by 169
Boumpas, D. T., Fessler, B. J., Austin III, H. A., Balow, J. E., Klippel, J. H., & Lockshin, M. D. (1995) · Annals of Internal Medicine · doi:10.7326/0003-4819-123-1-199507010-00007 · Cited by 168
Self-citationAntimalarial drugs in the treatment of rheumatological diseases.
Rynes, R. I. (1997) · Rheumatology · doi:10.1093/rheumatology/36.7.799 · Cited by 167
Biochemical characterization of ADP-ribose polymer metabolism in SLE
Chen, H.-Y., Pertusi, R., Kirkland, J., Rubin, B., & Jacobson, E. (1996) · Lupus · doi:10.1177/096120339600500105 · Cited by 162
Immunosuppressive potential of antimalarials
Salmeron, G., & Lipsky, P. E. (1983) · The American Journal of Medicine · doi:10.1016/0002-9343(83)91266-4 · Cited by 156
Stoll, T. M. (2004) · British journal of rheumatology · doi:10.1093/rheumatology/keh238 · Cited by 150
Borba, E. F., & Bonfá, E. (2001) · PubMed · Cited by 145
Wallace, D. J. (1994) · Rheumatic Disease Clinics of North America · doi:10.1016/s0889-857x(21)00233-7 · Cited by 143
Hydroxychloroquine in Decompensated, Treatment-Refractory Noninsulin-Dependent Diabetes Mellitus
Quatraro, A., Consoli, G., Magno, M., Caretta, F., Nardozza, A., Ceriello, A., & Giugliano, D. (1990) · Annals of Internal Medicine · doi:10.7326/0003-4819-112-9-678 · Cited by 140
Lakshminarayanan, S., Walsh, S. J., Mohanraj, M., et al. (2001) · PubMed · Cited by 139
Molad, Y., Gorshtein, A., Wysenbeek, A. J., Guedj, D., Majadla, R., Weinberger, A., & Amit-Vazina, M. (2002) · Lupus · doi:10.1191/0961203302lu203ra · Cited by 134
Nived, O., Jönsen, A., Bengtsson, A. A., Bengtsson, C., & Sturfelt, G. K. (2002) · PubMed · Cited by 132
Systemic lupus erythematosus in three ethnic groups. XX. Damage as a predictor of further damage
Alarcón, G. S. (2003) · British journal of rheumatology · doi:10.1093/rheumatology/keg481 · Cited by 128
Self-citationEffect of antimalarial agents on the fasting lipid profile in systemic lupus erythematosus.
Tam, L., Gladman, D. D., Hallett, D. C., Rahman, P., & Urowitz, M. B. (2000) · PubMed · Cited by 127
Does hydroxychloroquine sulfate prevent clot formation in systemic lupus erythematosus?
Wallace, D. J. (1987) · Arthritis & Rheumatism · doi:10.1002/art.1780301219 · Cited by 124
Inhibition of DNA and RNA polymerase reactions by chloroquine.
Cohen, S. N., & Yielding, K. L. (1965) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.54.2.521 · Cited by 118
Merrill, J. T., & Lahita, R. G. (1996) · Lupus · doi:10.1177/096120339600500103 · Cited by 118
Mechanism of Action of Antimalarial Drugs: Inhibition of Antigen Processing and Presentation
Fox, R. I., & Kang, H. (1993) · Lupus · doi:10.1177/0961203393002001031 · Cited by 104
Hodis, H. N., Quismorio, F. P., Wickham, E., & Blankenhorn, D. H. (1993) · PubMed · Cited by 103
Damage accrual in southern Chinese patients with systemic lupus erythematosus.
Mok, C. C., Ho, C. T. K., Wong, R. W. S., & Lau, C. S. (2003) · PubMed · Cited by 86
Antimalarials in rheumatology: Efficacy and safety
Maksymowych, W. P., & RUSSELL, A. S. (1987) · Seminars in Arthritis and Rheumatism · doi:10.1016/0049-0172(87)90023-0 · Cited by 82
Dj, W. (1996) · PubMed · Cited by 82
Antimalarials—the ‘real‘ advance in lupus
Wallace, D. J. (2001) · Lupus · doi:10.1191/096120301678646092 · Cited by 72
Prevention of Postoperative Deep Venous Thrombosis and Pulmonary Embolism
Carter, A. E., Eban, R. E., & Perrett, R. D. (1971) · BMJ · doi:10.1136/bmj.1.5744.312 · Cited by 71
Pilowsky, I. (1993) · Journal of Psychosomatic Research · doi:10.1016/0022-3999(93)90123-w · Cited by 71
The efficacy of antimalarials in systemic lupus erythematosus.
Rudnicki, R. D., Gresham, G. E., & Rothfield, N. F. (1975) · PubMed · Cited by 70
Bondeson, J., & Sundler, R. (1998) · General Pharmacology The Vascular System · doi:10.1016/s0306-3623(97)00269-3 · Cited by 69
Will some day PAPS fade into SLE?
Cabral, A., & Alarcón-Segovia, D. (1996) · Lupus · doi:10.1177/096120339600500102 · Cited by 67
Chloroquine Extends the Lifetime of the Activated Insulin Receptor Complex in Endosomes
Bevan, A. P., Krook, A., Tikerpae, J., Seabright, P. J., Siddle, K., & Smith, G. D. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.43.26833 · Cited by 63
Refractory Nephrotic Syndrome in Lupus Nephritis: Favorable Response to Indomethacin Therapy
Espinoza, L. R., Jara, L. J., Martínez-Osuna, P., Silveira, L. H., Cuellar, M. L., & Seleznick, M. J. (1993) · Lupus · doi:10.1177/096120339300200103 · Cited by 61
Hydroxychloroquine and postoperative thromboembolism after total hip replacement
Loudon, J. R. (1988) · The American Journal of Medicine · doi:10.1016/0002-9343(88)90364-6 · Cited by 60
Dj, W., Linker‐Israeli, M., Hyun, S., et al. (1994) · PubMed · Cited by 55
Chloroquine inhibits cyclization of squalene oxide to lanosterol in mammalian cells.
Chen, H. W., & Leonard, D. A. (1984) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)39707-7 · Cited by 46
Rustan, A. C., Nossen, J. Ø., Tefre, T., & Drevon, C. A. (1987) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/0167-4889(87)90004-8 · Cited by 32
Komuro (2001) · doi:10.1002/1529-0131(200112)44:12
D’Agostino (1998) · doi:10.1002/(sici)1097-0258(19981015)17:19<2265::aid-sim918>3.0.co;2-b
Cited by
KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases
Rovin, B. H., Adler, S. G., Barratt, J., Bridoux, F., Burdge, K. A., Chan, T. M., Cook, H. T., Fervenza, F. C., Gibson, K. L., Glassock, R. J., et al. (2021) · Kidney International · doi:10.1016/j.kint.2021.05.021 · Cited by 2,518
Hahn, B. H., McMahon, M. A., Wilkinson, A., Wallace, W. D., Daikh, D. I., FitzGerald, J. D., Karpouzas, G. A., Merrill, J. T., Wallace, D. J., Yazdany, J., et al. (2012) · Arthritis Care & Research · doi:10.1002/acr.21664 · Cited by 1,463
Bertsias, G. K., Tektonidou, M., Amoura, Z., Aringer, M., Bajema, I., Berden, J. H. M., Boletis, J., Cervera, R., Dörner, T., Doria, A., et al. (2012) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2012-201940 · Cited by 1,007
Ruiz-Irastorza, G., Ramos-Casals, M., Brito-Zeron, P., & Khamashta, M. A. (2010) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2008.101766 · Cited by 978
Systemic lupus erythematosus: Diagnosis and clinical management
Fava, A., & Petri, M. (2019) · Journal of Autoimmunity · doi:10.1016/j.jaut.2018.11.001 · Cited by 754
Metadata
- Authors
- Fessler, B. J., Alarcón, G. S., McGwin, G., Roseman, J., Bastian, H. M., Friedman, A. W., Baethge, B. A., Vilá, L., Reveille, J. D., & for the LUMINA Study Group
- Venue
- Arthritis & Rheumatism
- Publisher
- Wiley
- Published
- 2005-05
- Volume
- 52
- Issue
- 5
- Pages
- 1473-1480
- ISSN
- 0004-3591 (ISSN-L)
- 1529-0131
- OpenAlex
- W2029002123
- Cited by
- 377
- References
- 66
- FWCI
- 9.20
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.